CoChat

Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease

Open access
Raket, Lars Lau, Oudin Åström, Daniel, Norlin, Jenny M., Kellerborg, Klas, Martinez-Martin, Pablo, Odin, Per · 2022 · Scientific Reports

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Parkinson’s disease (PD) is typically considered an age-related disease, but the age at disease onset can vary by decades between patients. Aging and aging-associated diseases can affect the movement system independently of PD, and advanced age has previously been proposed to be associated with a more severe PD phenotype with accelerated progression. In this work, we investigated how interactions between PD progression and aging affect a wide range of outcomes related to PD motor and nonmotor symptoms as well as Health Related Quality of Life (HRQoL) and treatment characteristics. This population-based cohort study is based on 1436 PD patients from southern Sweden followed longitudinally for up to approximately 7.5 years from enrollment (3470 visits covering 2285 patient years, average follow-up time 1.7 years). Higher age at onset was generally associated with faster progression of motor symptoms, with a notable exception of dyskinesia and other levodopa-associated motor fluctuations that had less severe trajectories for patients with higher age at onset. Mixed results were observed for emergence of non-motor symptoms, while higher age at onset was generally associated with worse HRQoL trajectories. Accounting for these identified age-associated differences in disease progression could positively impact patient management and drug development efforts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-021-04356-8

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Baseline Spearman correlations between time variables (age at Parkinson’s Disease onset, age at Parkinson’s Disease diagnosis, age at baseline, years since Parkinson’s Disease onset, years since Parkinson’s Disease diagnosis), and respectively, symptom-based outcomes, Health related Quality of Life outcomes, and treatment outcomes.
Figure 1 Baseline Spearman correlations between time variables (age at Parkinson’s Disease onset, age at Parkinson’s Disease diagnosis, age at baseline, years since Parkinson’s Disease onset, years since Parkinson’s Disease diagnosis), and respectively, symptom-based outcomes, Health related Quality of Life outcomes, and treatment outcomes.CC BY · PubMed Central
Figure 2 Patient ages at study visits against patient age at onset. The black line represents age at onset, the orange line represents 7.5 years after onset, and the dark red line represents 15 years after onset.
Figure 2 Patient ages at study visits against patient age at onset. The black line represents age at onset, the orange line represents 7.5 years after onset, and the dark red line represents 15 years after onset.CC BY · PubMed Central
Figure 3 Estimated 15-year mean trajectories of CISI-PD outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2298 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.
Figure 3 Estimated 15-year mean trajectories of CISI-PD outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2298 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.CC BY · PubMed Central
Figure 4 Estimated 15-year mean trajectories of staging and motor fluctuation outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2307 visits (Hoehn & Yahr) and 2510 visits (motor fluctuation outcomes). Dotted line represents the estimated mean scores for patients with onset at the given age.
Figure 4 Estimated 15-year mean trajectories of staging and motor fluctuation outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2307 visits (Hoehn & Yahr) and 2510 visits (motor fluctuation outcomes). Dotted line represents the estimated mean scores for patients with onset at the given age.CC BY · PubMed Central
Figure 5 Estimated 15-year mean trajectories of Non-Motor Symptom Questionnaire outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2758 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.
Figure 5 Estimated 15-year mean trajectories of Non-Motor Symptom Questionnaire outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2758 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.CC BY · PubMed Central
Figure 6 Estimated 15-year mean trajectories of 8-item Parkinson’s Disease Questionnaire outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2421 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.
Figure 6 Estimated 15-year mean trajectories of 8-item Parkinson’s Disease Questionnaire outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 2421 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.CC BY · PubMed Central
Figure 7 Estimated 15-year mean trajectories of EQ5D-3L outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 1800 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.
Figure 7 Estimated 15-year mean trajectories of EQ5D-3L outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 1800 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.CC BY · PubMed Central
Figure 8 Estimated 15-year mean trajectories of treatment outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 205,463 prescriptions and pick-ups mapped to 3407 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.
Figure 8 Estimated 15-year mean trajectories of treatment outcomes from Parkinson’s disease onset at respectively 45, 55, 65, and 75 years of age. Trajectories estimated based on data from 205,463 prescriptions and pick-ups mapped to 3407 visits. Dotted line represents the estimated mean scores for patients with onset at the given age.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 72

Metadata

Authors
Raket, L. L., Oudin Åström, D., Norlin, J. M., Kellerborg, K., Martinez-Martin, P., & Odin, P.
Affiliations
  • Swedish Institute for Health Economics (SE)
  • Lund University (SE)
Corresponding author
Odin, Per
Venue
Scientific Reports
Published
2022-01-11
Volume
12
Issue
1
Pages
526-526
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4205777611
Cited by
72
References
28
Citations by year
2026: 17 · 2025: 22 · 2024: 18 · 2023: 8 · 2022: 7
FWCI
7.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Lundbeck A/S
  • The Swedish National Government and County Councils
  • Skåne University Hospital Foundations and Donations
  • Lund University Medical Faculty
  • Swedish Parkinson Academy
  • Multipark
  • Lund University
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Parkinson's disease, age of onset, disease progression, aging, motor symptoms, non-motor symptoms, health-related quality of life, dyskinesia, antiparkinsonian therapy, symptom trajectories
MeSH terms
Aged, Aged, 80 and over, Antiparkinson Agents, Female, Humans, Levodopa, Longitudinal Studies, Male, Middle Aged, Parkinson Disease, Quality of Life, Sweden, Cohort Studies, Age of Onset, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease. https://app.cochat.ai/papers/10.1038/s41598-021-04356-8
The paper
Raket, L. L., Oudin Åström, D., Norlin, J. M., Kellerborg, K., Martinez-Martin, P., & Odin, P. (2022). Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease. Scientific Reports. https://doi.org/10.1038/s41598-021-04356-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.